Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00974311 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,199
- Enrollment target
NCT00974311 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,199 participants.
The verdict
NCT00974311, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,199 participants
- Enrollment target
Study Summary
This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.
Interventions
- DRUG Placebo
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,199 participants |
| Start Date | 2009-09-30 |
| Est. Completion | 2017-11-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00974311
The ClinicalTrials.gov registry entry for NCT00974311 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00974311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00974311 about?
NCT00974311 is a clinical study titled "Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy". This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.
What is the current status of trial NCT00974311?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,199 participants. The study started on 2009-09-30. Estimated completion is 2017-11-02.
What interventions are being tested in trial NCT00974311?
The interventions under investigation include: Placebo (DRUG), Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT00974311?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.